What the research found
The hepatotoxicity of 17α-alkylated steroids (17AAs) stems from their chemical structure—specifically the alkylation at the 17-carbon position—rather than the route of administration. This structural modification extends the steroid's half-life, allowing it to persist in the body far longer than unmodified steroids. According to the Bond and Llewellyn framework presented, liver toxicity scales with both half-life and androgen receptor activation potency; a steroid's damaging potential is essentially the product of how long it circulates and how strongly it activates the androgen receptor.
A widespread belief holds that sublingual or buccal dosing of 17AAs reduces liver damage by sidestepping first-pass hepatic metabolism. The analysis challenges this: while these routes do bypass immediate liver processing, the steroid still circulates systemically and exposes the liver repeatedly over hours or days. Injectable 17AAs (like trenbolone or superdrol) face the same problem—they avoid first-pass metabolism but remain hepatotoxic because the liver encounters them repeatedly as they circulate. The source emphasizes that the risk comes from the molecule itself, not how it enters the bloodstream.
Early warning signs of 17AA-induced liver stress include fatigue, nausea, and elevation in liver enzymes (ALT, AST, GGT); severe toxicity can progress to jaundice and tumours. The distinction between 17AAs and esterified injectables (like testosterone enanthate or nandrolone) remains clinically important: esterified compounds are rapidly hydrolysed in circulation and cleared, whereas 17AAs resist metabolism and accumulate.
Why it matters for you
If you're running 17AAs—whether oral (methyltestosterone, superdrol, methasterone) or injectable (trenbolone)—the route doesn't offer a safety advantage. Switching from tablets to sublingual or to injectables won't meaningfully reduce liver burden. What matters is the compound's half-life and potency. This means your protocol design should prioritize cycle duration and dose, not administration method. Shorter cycles with lower total exposure will better protect your liver than trying to "outsmart" hepatotoxicity through route selection.
Liver enzyme monitoring becomes non-negotiable. If you track biomarkers via MyKine, ALT, AST, and GGT should be baseline, mid-cycle, and post-cycle checkpoints whenever you use 17AAs. Elevated enzymes may precede symptoms, so relying on fatigue or nausea alone is risky. Pairing blood work with practical steps—limiting cycle length, avoiding alcohol, and considering hepatoprotective agents—gives you concrete data to adjust or stop if damage is accumulating.
The misconception that injectable 17AAs are "liver-safe" can tempt users toward higher doses or longer runs. Understanding that the liver sees the same toxic compound regardless of injection versus oral intake should inform your risk calculus and cycle planning.
Caveats
- The Bond and Llewellyn Hypothesis is presented as a conceptual framework, not a validated clinical model; individual responses vary widely
- No human clinical trials or effect-size data are provided; the argument is largely mechanistic and theoretical
- Limited discussion of dose-response relationships or threshold toxicity levels
- The source does not address inter-individual genetic variation in steroid metabolism or liver enzyme capacity
- Hepatoprotective strategies are mentioned but not detailed or evidence-graded